Certified Diabetes Educator Practice Exam

Meglitinides are a class of oral hypoglycemic agents used in the management of type 2 diabetes. They work by stimulating the pancreas to release insulin in response to meals, which helps regulate blood sugar levels. A significant side effect associated with Meglitinides is hypoglycemia. This occurs because these medications can lead to an excessive release of insulin, particularly if a meal is skipped after taking the medication or if the dosage is not properly adjusted to the individual's needs.

Hypoglycemia presents itself as symptoms like shakiness, sweating, confusion, and in severe cases, can lead to loss of consciousness or seizures. It is essential for individuals using Meglitinides to monitor their blood sugar levels regularly and to recognize the signs of hypoglycemia in order to manage their condition effectively.

The other side effects mentioned, such as nausea or weight loss, are not directly related to the primary action of Meglitinides. While some patients might experience nausea, it is not a common or significant side effect linked specifically to this class of drugs. Weight loss is generally not a typical outcome of using Meglitinides; in fact, the use of these medications might not influence weight at all for many individuals. Lastly, hyperglycemia would occur